Healthcare | San Francisco

InCarda Therapeutics Raises $30 Million Series C Equity Financing for Inhaled Heart-Disease Medicine

InCarda Therapeutics, developing inhaled therapies for cardiovascular diseases, raised $30 million in Series C equity financing, led by an affiliate of Innoviva, Inc. with existing investors Deerfield Management, HealthCap and Morningside Ventures participating. Funds will be used to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), to self-treat recent-onset paroxysmal atrial fibrillation (PAF). [Full story]